Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 13:17:39 +0200Mon, 13 May 2024 11:18:00 +0200Human medicines European public assessment report (EPAR): Reblozyl, luspatercept, Date of authorisation: 25/06/2020, Revision: 7, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/reblozylHuman medicines European public assessment report (EPAR): Reblozyl, luspatercept, Date of authorisation: 25/06/2020, Revision: 7, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/reblozylMon, 13 May 2024 11:18:00 +0200Human medicineReblozyl : EPAR - All authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/h-4444-aa_en.pdfReblozyl : EPAR - All authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/h-4444-aa_en.pdfWed, 08 Jul 2020 16:53:00 +0200Human medicine